Evidence map›Paper›PMID 37368037›Full record

ArticleRheumatology international2023

Assessment of antibody levels to SARS-CoV-2 in patients with idiopathic inflammatory myopathies receiving treatment with intravenous immunoglobulin.

Sangmee Sharon Bae, Emmanuelle Faure-Kumar, Kathie Ferbas, Jennifer Wang, Ani Shahbazian, Linh Truong, Howard Yang, Maureen McMahon, John D FitzGerald, Christina Charles-Schoeman

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sangmee Sharon BaeDavid Geffen School of Medicine, Division of Rheumatology, University of California Los Angeles, Los Angeles, CA, USA. sbae@mednet.ucla.edu.ORCID http://orcid.org/0000-0002-7216-7219
Emmanuelle Faure-KumarDavid Geffen School of Medicine, Vatche and Tamar Manoukian Division of Digestive Diseases, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0009-0005-6992-8880
Kathie FerbasDavid Geffen School of Medicine, Department of Pediatrics, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0009-0005-8861-2240
Jennifer WangDavid Geffen School of Medicine, Division of Rheumatology, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0009-0007-2315-9531
Ani ShahbazianDavid Geffen School of Medicine, Division of Rheumatology, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0009-0000-9808-4406
Linh TruongDavid Geffen School of Medicine, Division of Rheumatology, University of California Los Angeles, Los Angeles, CA, USA.
Howard YangDavid Geffen School of Medicine, Division of Rheumatology, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0009-0004-6361-8630
Maureen McMahonDavid Geffen School of Medicine, Division of Rheumatology, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-2910-7640
John D FitzGeraldDavid Geffen School of Medicine, Division of Rheumatology, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-8419-7538
Christina Charles-SchoemanDavid Geffen School of Medicine, Division of Rheumatology, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-1768-7019
University of California, Los Angeles · US

Funding

Rheumatology Research Foundation Scientist Development Award
6 · The paper itself

Abstract

Antibodies to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) have been reported in pooled healthy donor plasma and intravenous immunoglobulin products (IVIG). It is not known whether administration of IVIG increases circulating anti-SARS-CoV-2 antibodies (COVID ab) in IVIG recipients. COVID ab against the receptor binding domain of the spike protein were analyzed using a chemiluminescent microparticle immunoassay in patients with idiopathic inflammatory myopathies (IIM) both receiving and not receiving IVIG (IVIG and non-IVIG group, respectively). No significant differences in COVID ab levels were noted between IVIG and non-IVIG groups (417 [67-1342] AU/mL in IVIG vs 5086 [43-40,442] AU/mL in non-IVIG, p = 0.11). In linear regression models including all post-vaccination patient samples, higher number of vaccine doses was strongly associated with higher COVID ab levels (2.85 [1.21, 4.48] log AU/mL, regression coefficient [Formula: see text] [95% CI], p = 0.001), while use of RTX was associated with lower ab levels (2.73 [- 4.53, - 0.93] log AU/mL, [Formula: see text][95%CI], p = 0.004). In the IVIG group, higher total monthly doses of IVIG were associated with slightly higher COVID ab levels (0.02 [0.002-0.05] log AU/mL, p = 0.04). While patients on IVIG did not have higher COVID ab levels compared to the non-IVIG group, higher monthly doses of IVIG were associated with higher circulating levels of COVID ab in patients receiving IVIG, particularly in patients concomitantly receiving RTX. Our findings suggest that IIM patients, especially those at increased risk of COVID infection and worse COVID outcomes due to RTX therapy may have protective benefits when on concurrent IVIG treatment.

Indexed as

COVID-19MyositisAntibodies, ViralHumansImmunoglobulins, IntravenousSARS-CoV-2VaccinationAntibodies, ViralImmunoglobulins, IntravenousAnti-SARS-CoV2 antibodiesDermatomyositisIdiopathic inflammatory myopathiesIntravenous immunoglobulinPolymyositis

Identifiers

PMID37368037
PMCPMC10348966
OpenAlexW4382182386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.